

Liver Fibrosis Drug-Asia Pacific Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/LDFD9EC333FEN.html>

Date: February 2018

Pages: 132

Price: US\$ 3,480.00 (Single User License)

ID: LDFD9EC333FEN

Abstracts

Report Summary

Liver Fibrosis Drug-Asia Pacific Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Liver Fibrosis Drug industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole Asia Pacific and Regional Market Size of Liver Fibrosis Drug 2013-2017, and development forecast 2018-2023

Main market players of Liver Fibrosis Drug in Asia Pacific, with company and product introduction, position in the Liver Fibrosis Drug market

Market status and development trend of Liver Fibrosis Drug by types and applications

Cost and profit status of Liver Fibrosis Drug, and marketing status

Market growth drivers and challenges

The report segments the Asia Pacific Liver Fibrosis Drug market as:

Asia Pacific Liver Fibrosis Drug Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

China

Japan

Korea

India

Southeast Asia

Australia

Asia Pacific Liver Fibrosis Drug Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Interferon

Maloti Lipid

Nucleoside

Other

Asia Pacific Liver Fibrosis Drug Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Research Center

Hospital

Clinic

Asia Pacific Liver Fibrosis Drug Market: Players Segment Analysis (Company and Product introduction, Liver Fibrosis Drug Sales Volume, Revenue, Price and Gross Margin):

Bird Rock Bio, Inc.

Bristol-Myers Squibb Company

Celgene Corporation

Dicerna Pharmaceuticals, Inc.

Digna Biotech, S.L.

Genfit SA

Gilead Sciences, Inc.

GNI Group Ltd.

HEC Pharm Co., Ltd.

Dr. Falk Pharma GmbH

LG Life Science LTD.

Nitto Denko Corporation

Pfizer Inc.

Pharmaxis Limited

Promedior, Inc.

Dynavax Technologies Corporation

Evotec AG

FibroGen, Inc.

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF LIVER FIBROSIS DRUG

- 1.1 Definition of Liver Fibrosis Drug in This Report
- 1.2 Commercial Types of Liver Fibrosis Drug
 - 1.2.1 Interferon
 - 1.2.2 Maloti Lipid
 - 1.2.3 Nucleoside
 - 1.2.4 Other
- 1.3 Downstream Application of Liver Fibrosis Drug
 - 1.3.1 Research Center
 - 1.3.2 Hospital
 - 1.3.3 Clinic
- 1.4 Development History of Liver Fibrosis Drug
- 1.5 Market Status and Trend of Liver Fibrosis Drug 2013-2023
 - 1.5.1 Asia Pacific Liver Fibrosis Drug Market Status and Trend 2013-2023
 - 1.5.2 Regional Liver Fibrosis Drug Market Status and Trend 2013-2023

CHAPTER 2 ASIA PACIFIC MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Liver Fibrosis Drug in Asia Pacific 2013-2017
- 2.2 Consumption Market of Liver Fibrosis Drug in Asia Pacific by Regions
 - 2.2.1 Consumption Volume of Liver Fibrosis Drug in Asia Pacific by Regions
 - 2.2.2 Revenue of Liver Fibrosis Drug in Asia Pacific by Regions
- 2.3 Market Analysis of Liver Fibrosis Drug in Asia Pacific by Regions
 - 2.3.1 Market Analysis of Liver Fibrosis Drug in China 2013-2017
 - 2.3.2 Market Analysis of Liver Fibrosis Drug in Japan 2013-2017
 - 2.3.3 Market Analysis of Liver Fibrosis Drug in Korea 2013-2017
 - 2.3.4 Market Analysis of Liver Fibrosis Drug in India 2013-2017
 - 2.3.5 Market Analysis of Liver Fibrosis Drug in Southeast Asia 2013-2017
 - 2.3.6 Market Analysis of Liver Fibrosis Drug in Australia 2013-2017
- 2.4 Market Development Forecast of Liver Fibrosis Drug in Asia Pacific 2018-2023
 - 2.4.1 Market Development Forecast of Liver Fibrosis Drug in Asia Pacific 2018-2023
 - 2.4.2 Market Development Forecast of Liver Fibrosis Drug by Regions 2018-2023

CHAPTER 3 ASIA PACIFIC MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole Asia Pacific Market Status by Types

- 3.1.1 Consumption Volume of Liver Fibrosis Drug in Asia Pacific by Types
- 3.1.2 Revenue of Liver Fibrosis Drug in Asia Pacific by Types
- 3.2 Asia Pacific Market Status by Types in Major Countries
 - 3.2.1 Market Status by Types in China
 - 3.2.2 Market Status by Types in Japan
 - 3.2.3 Market Status by Types in Korea
 - 3.2.4 Market Status by Types in India
 - 3.2.5 Market Status by Types in Southeast Asia
 - 3.2.6 Market Status by Types in Australia
- 3.3 Market Forecast of Liver Fibrosis Drug in Asia Pacific by Types

CHAPTER 4 ASIA PACIFIC MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Liver Fibrosis Drug in Asia Pacific by Downstream Industry
- 4.2 Demand Volume of Liver Fibrosis Drug by Downstream Industry in Major Countries
 - 4.2.1 Demand Volume of Liver Fibrosis Drug by Downstream Industry in China
 - 4.2.2 Demand Volume of Liver Fibrosis Drug by Downstream Industry in Japan
 - 4.2.3 Demand Volume of Liver Fibrosis Drug by Downstream Industry in Korea
 - 4.2.4 Demand Volume of Liver Fibrosis Drug by Downstream Industry in India
 - 4.2.5 Demand Volume of Liver Fibrosis Drug by Downstream Industry in Southeast Asia
 - 4.2.6 Demand Volume of Liver Fibrosis Drug by Downstream Industry in Australia
- 4.3 Market Forecast of Liver Fibrosis Drug in Asia Pacific by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF LIVER FIBROSIS DRUG

- 5.1 Asia Pacific Economy Situation and Trend Overview
- 5.2 Liver Fibrosis Drug Downstream Industry Situation and Trend Overview

CHAPTER 6 LIVER FIBROSIS DRUG MARKET COMPETITION STATUS BY MAJOR PLAYERS IN ASIA PACIFIC

- 6.1 Sales Volume of Liver Fibrosis Drug in Asia Pacific by Major Players
- 6.2 Revenue of Liver Fibrosis Drug in Asia Pacific by Major Players
- 6.3 Basic Information of Liver Fibrosis Drug by Major Players
 - 6.3.1 Headquarters Location and Established Time of Liver Fibrosis Drug Major Players
 - 6.3.2 Employees and Revenue Level of Liver Fibrosis Drug Major Players

- 6.4 Market Competition News and Trend
 - 6.4.1 Merger, Consolidation or Acquisition News
 - 6.4.2 Investment or Disinvestment News
 - 6.4.3 New Product Development and Launch

CHAPTER 7 LIVER FIBROSIS DRUG MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

- 7.1 Bird Rock Bio, Inc.
 - 7.1.1 Company profile
 - 7.1.2 Representative Liver Fibrosis Drug Product
 - 7.1.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Bird Rock Bio, Inc.
- 7.2 Bristol-Myers Squibb Company
 - 7.2.1 Company profile
 - 7.2.2 Representative Liver Fibrosis Drug Product
 - 7.2.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb Company
- 7.3 Celgene Corporation
 - 7.3.1 Company profile
 - 7.3.2 Representative Liver Fibrosis Drug Product
 - 7.3.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Celgene Corporation
- 7.4 Dicerna Pharmaceuticals, Inc.
 - 7.4.1 Company profile
 - 7.4.2 Representative Liver Fibrosis Drug Product
 - 7.4.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Dicerna Pharmaceuticals, Inc.
- 7.5 Digna Biotech, S.L.
 - 7.5.1 Company profile
 - 7.5.2 Representative Liver Fibrosis Drug Product
 - 7.5.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Digna Biotech, S.L.
- 7.6 Genfit SA
 - 7.6.1 Company profile
 - 7.6.2 Representative Liver Fibrosis Drug Product
 - 7.6.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Genfit SA
- 7.7 Gilead Sciences, Inc.
 - 7.7.1 Company profile

- 7.7.2 Representative Liver Fibrosis Drug Product
- 7.7.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Gilead Sciences, Inc.
- 7.8 GNI Group Ltd.
 - 7.8.1 Company profile
 - 7.8.2 Representative Liver Fibrosis Drug Product
 - 7.8.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of GNI Group Ltd.
- 7.9 HEC Pharm Co., Ltd.
 - 7.9.1 Company profile
 - 7.9.2 Representative Liver Fibrosis Drug Product
 - 7.9.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of HEC Pharm Co., Ltd.
- 7.10 Dr. Falk Pharma GmbH
 - 7.10.1 Company profile
 - 7.10.2 Representative Liver Fibrosis Drug Product
 - 7.10.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Dr. Falk Pharma GmbH
- 7.11 LG Life Science LTD.
 - 7.11.1 Company profile
 - 7.11.2 Representative Liver Fibrosis Drug Product
 - 7.11.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of LG Life Science LTD.
- 7.12 Nitto Denko Corporation
 - 7.12.1 Company profile
 - 7.12.2 Representative Liver Fibrosis Drug Product
 - 7.12.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Nitto Denko Corporation
- 7.13 Pfizer Inc.
 - 7.13.1 Company profile
 - 7.13.2 Representative Liver Fibrosis Drug Product
 - 7.13.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Pfizer Inc.
- 7.14 Pharmaxis Limited
 - 7.14.1 Company profile
 - 7.14.2 Representative Liver Fibrosis Drug Product
 - 7.14.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Pharmaxis Limited
- 7.15 Promedior, Inc.
 - 7.15.1 Company profile
 - 7.15.2 Representative Liver Fibrosis Drug Product

- 7.15.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Promedior, Inc.
- 7.16 Dynavax Technologies Corporation
- 7.17 Evotec AG
- 7.18 FibroGen, Inc.

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF LIVER FIBROSIS DRUG

- 8.1 Industry Chain of Liver Fibrosis Drug
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF LIVER FIBROSIS DRUG

- 9.1 Cost Structure Analysis of Liver Fibrosis Drug
- 9.2 Raw Materials Cost Analysis of Liver Fibrosis Drug
- 9.3 Labor Cost Analysis of Liver Fibrosis Drug
- 9.4 Manufacturing Expenses Analysis of Liver Fibrosis Drug

CHAPTER 10 MARKETING STATUS ANALYSIS OF LIVER FIBROSIS DRUG

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Reference

I would like to order

Product name: Liver Fibrosis Drug-Asia Pacific Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/LDFD9EC333FEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/LDFD9EC333FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970